ADAFSA closes Zaiqa Grill N Restaurant in Abu Dhabi
Abu Dhabi: The Abu Dhabi Agriculture and Food Safety Authority (ADAFSA) has issued a decision to administratively close " Zaiqa Grill N Restaurant L.L.C." located in Al Dana, Abu Dhabi (CN-5255566), due to violations of Law No. (2) of 2008 on food safety in the Emirate of Abu Dhabi and its associated regulations. Furthermore, the establishment's practices pose a serious risk to public health.
ADAFSA clarified that the food control report indicated that the administrative closure decision was issued due to repeated food safety violations and the failure to implement effective corrective measures, necessitating an immediate intervention to safeguard food safety and consumer health.
The Authority also affirmed that the administrative closure order will remain in effect as long as its causes exist. The establishment may resume operations after rectifying its situation and fulfilling all the necessary requirements for practicing the activity, and removing the causes of the violation.
In addition, ADAFSA highlighted that the closure and the identification of observed violations are part of ongoing inspection efforts to strengthen the food safety system in the Emirate of Abu Dhabi. It underscores its supervisory role in ensuring that all establishments comply with food safety requirements. All types of establishments and food products are subject to periodic inspections by ADAFSA's inspectors to guarantee compliance with the highest food safety standards.
The Authority also encourages the public to communicate with them and report any violations detected in any food establishment, such as non-compliance or suspicion of food content, by calling the toll-free number for the Abu Dhabi Government, 800555. ADAFSA's inspectors will take the necessary measures to ensure the delivery of safe and sound food to all members of the community in the Emirate of Abu Dhabi.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
11 hours ago
- The National
Some microplastics pollute water more than others
Microplastics are one of the biggest threats to global water health, with research piling up to show they are everywhere, from oceans and rivers to the air we breathe. The biggest culprits are synthetic textiles and car tyres. A single washing machine load of acrylic clothes − made from a synthetic material often used as a wool substitute − can release an estimated 730,000 fibres into wastewater, according to Plymouth University. The International Union for Conservation of Nature (IUCN) estimates that man-made fabrics account for thirty-five per cent of all primary microplastics in the ocean. Car tyres, the second-largest source at 28 per cent, shed micro and nano-particles as they erode during driving, contaminating the air, soil and waterways. But the problem is bigger than just fast fashion and transport. Microplastics come from other everyday items, such as cleaning products and road markings, making them nearly impossible to avoid. World Ocean Day June 8 marked World Oceans Day, spotlighting the urgent need to protect our seas. In the UAE, Dr Amna Al Dahak, Minister of Climate Change and Environment, warned that the health of the world's oceans is at serious risk: 'Covering more than 70 per cent of the Earth's surface, our oceans are undeniably essential to human lives and livelihoods,' she said. Abu Dhabi has led the region's fight against plastic pollution, introducing a single-use plastic ban on June 1, 2022. By the end of 2024, the campaign had removed 360 million plastic bags from circulation. Globally, the numbers are staggering. According to the UN Environment Programme, humans have produced 9.2 billion tonnes of plastic since the 1950s — 7 billion tonnes of which is now waste. By 2060, plastic waste could nearly triple to one billion tonnes annually if current trends continue. 'Plastic pollution is one of the gravest environmental threats facing Earth,' said Elisa Tonda at the UNEP. 'But it's a problem we can solve.' The Human Impact Emerging research in animal and human cells suggests microplastics may be linked to cancer, heart disease, and reproductive problems. In the UAE, the urgency hits close to home. 'We eat seafood. That plastic enters our food chain, and it stays in our bodies. It's toxic. This isn't just about the environment — it's about public health,' said Ms Al Mazrouei.
Zawya
12 hours ago
- Zawya
ProvenMed appoints Global Health Strategist Bita Bani as Chief Growth Officer to lead international expansion
Abu Dhabi, UAE – ProvenMed, a pioneering MedTech company transforming continence care and digital home diagnostics, proudly announces the appointment of Bita Bani as its new Chief Growth Officer (CGO). This strategic hire comes at a critical juncture, as ProvenMed experiences a significant spike in international interest following its participation in major healthcare and medtech events across the globe. Bita Bani, a seasoned business development executive with an extensive track record in global health ventures, joins ProvenMed to lead its next phase of international expansion. Countries across South America, Europe, North America, and the GCC have expressed serious interest—making it imperative to transition from momentum to structured growth according to Bita. 'After an incredible response from global markets, it's time to scale up,' said Amine Staali, CEO of ProvenMed. 'Bita's deep experience in building strategic partnerships and leading growth in diverse healthcare environments will be instrumental in maximizing the momentum we've gained. With her leadership, we are ready to translate international interest into sustainable market entry and commercial success.' Bita Bani has successfully guided numerous healthtech companies through growth phases spanning market access, licensing, and commercialization. She is known for aligning ambitious go-to-market strategies with real-world healthcare needs, and for forging high-impact collaborations across public and private sectors. 'I'm thrilled to join ProvenMed at such a pivotal stage,' said Bita Bani. 'This is a company driven by purpose and powered by innovation. With the right strategic framework, I believe we can make these technologies accessible to millions of people who need them most.' As ProvenMed continues to build a robust presence across MENA, Bita Bani's experience is expected to enhance the company's strategic expansion and revenue diversification efforts across Europe, and North America as well. With Bita's leadership, ProvenMed is poised to accelerate global adoption of its groundbreaking solutions, forging new pathways in patient-centric digital health About ProvenMed ProvenMed is a medical technology company developing innovative solutions in continence care and at home digital diagnostics. Its sub-brands include: ActivGo® – A discreet wearable for male urinary incontinence. Livv® – Ai-powered digital home lab and testing kits for home use. Together, they empower users with autonomy, privacy, and real-time health insights, promoting dignity and health access across all populations.
Zawya
15 hours ago
- Zawya
Dubai emerges as a regional hub for gene therapy breakthroughs
Medcare Royal Speciality Hospital is pioneering treatments for rare diseases including Spinal Muscular Atrophy and Duchenne Muscular Dystrophy, potentially saving young lives with a single treatment. Dubai – Dubai is rapidly establishing itself as a hub for cutting-edge gene therapy, with Medcare Royal Speciality Hospital Al Qusais being at the forefront of treating rare genetic disorders such as Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD). With the hospital's proximity to the Dubai International Airport, a growing number of patients from Turkey, and other countries in the region and beyond are traveling to Dubai for life changing treatments. Medcare has been redefining excellence in the field of paediatric neurology and gene-based therapies, pioneering a new era of hope and healing for families affected by such debilitating conditions. Turkish families are increasingly turning to Medcare for SMA treatments, with incidence rates in Turkey significantly higher than the global average. The hospital's state-of-the-art facilities, international medical expertise, and holistic treatment model position it as a Centre of Excellence for gene disorders, not just in the UAE but across the MENA and the Asia-Pacific regions. SMA, a rare neurodegenerative condition, causes progressive muscle weakness and often proves fatal in infancy if left untreated. In Turkey, SMA affects 1 in every 6,000 births compared to 1 in 10,000 globally [i]. According to the Turkish health authorities, there are currently over 3,000 people living with SMA, and about 150 new cases are diagnosed each year. DMD, another severe neuromuscular disorder, affects over 4,000 genetically confirmed patients in Turkey [ii]. Under the leadership of Dr. Vivek Mundada, a British Board-certified Consultant Paediatric Neurologist at Medcare Royal Speciality Hospital has delivered remarkable outcomes in managing these complex genetic conditions. Unlike traditional therapies that require ongoing spinal injections, Medcare offers a one-time, potentially curative gene therapy that addresses the root cause of the condition, dramatically improving the quality of life and long-term health. Medcare is the first private healthcare provider outside the U.S.A. to successfully administer gene therapy for SMA in the MENA region, having delivered over 100 infusions to date at Medcare Women & Children Hospital. 'Dubai is becoming a center of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' said Dr. Vivek Mundada, Consultant Paediatric Neurologist at Medcare Royal Speciality Hospital. 'Through our comprehensive, patient-centered care model, we are transforming outcomes for children who previously had limited treatment options.' Medcare's approach goes beyond clinical excellence. Patients benefit from a multidisciplinary team that includes experts in neurology, pulmonology, orthopaedics, rehabilitation, and genetic counselling. The hospital also provides continuous follow-up care for international patients after they return home. Turkish families have already seen outstanding results. One such story is that of Mirha, diagnosed with SMA just nine days after she was born. In 2024, she underwent gene therapy at Medcare and is now thriving without the need for breathing or feeding support. Similarly, Elif Bade who was treated in March 2024 when she was just 2 years old, has shown remarkable progress following her gene therapy at Medcare. The parents of Mirha remarked, 'We cannot express enough gratitude to Dr. Mundada and the Medcare team. Thanks to the expert and compassionate care in Dubai, our daughter has been given a new lease on life.' Aligned with the UAE's vision to be a global hub for medical innovation and excellence, Medcare continues to invest in infrastructure, talent, and technology to offer best-in-class care. The newly launched rare disease unit at Medcare Royal Speciality Hospital in Dubai offers AI-powered diagnostics, robotic surgery, and advanced quaternary care, reinforcing its leadership in rare disease management. As part of Aster DM Healthcare, Medcare is committed to expanding access to advanced medical care for international patients, while contributing to the UAE's growing medical tourism sector, where families seek top-tier, cost-effective care without long wait times, especially for critical and time-sensitive conditions like the rare genetic disorders. About Medcare: Medcare is the premium private healthcare provider under the parent group, Aster DM Healthcare. Operating leading state-of-the-art Hospitals, including Medcare Multi-specialty Hospital in Dubai and Sharjah, Medcare Women & Children Hospital, Medcare Orthopaedics and Spine Hospital, and 20 medical centres in the UAE, Medcare has established a strong presence in the UAE. Medcare is dedicated to offering premium integrated health services in accordance with the highest quality. From talent to technology to facilities and treatment, Medcare maintains the highest possible standards in healthcare delivery. All Medcare hospitals and medical centres are accredited by the Joint Commission International (JCI), which is considered the gold standard in global healthcare. Apart from this, Medcare facilities have won several certifications. What sets Medcare apart is its exceptional multi-cultural, multi-lingual team of doctors who have received extensive training from some of the top-notch medical institutes around the world. Using a multidisciplinary approach, the Medcare team provides optimal, evidence-based treatments to patients, with the support of trained nurses, dieticians, rehabilitation therapists and technologists. Living by its simple promise 'We'll Treat You Well', Medcare's team is fully committed to providing high-quality, personalized medical care to every patient. For more information on Medcare visit or follow @Medcareae For media queries, please contact: Akshara Suresh Watermelon Communications Dubai, U.A.E. Email – akshara@
